Insights

VWV are delighted to have acted for the sellers of Renascience Pharma in the sale of the company to pharmaceutical major Lupin, through its UK subsidiary.

Medicine shortages are an important issue in the UK, with significant implications for patients and healthcare professionals, as well as suppliers and distributors, and the wider health system. 

Following the Government's publication of the 10 year Industrial Strategy, it has now published its sector plans for its eight growth sectors (the IS-8) - one of which being the Life Sciences Sector Plan. But what does it say?

In the recent Life Sciences Sector Plan, one of the promises to make the UK the third best place in the world for life sciences was to streamline regulation and market access.

The UK has taken a massive step forward in the holy grail of personalised medicine by introducing new regulations that enable treatments to be prepared and delivered directly at the point of care.

In May, the government published its response to the Intellectual Property Office's (UK IPO) consultation on the UK's future exhaustion regime for intellectual property rights (IPR). The government has announced that the current UK+ exhaustion regime will continue in place.